source
- Merck, Daiichi end plans to seek speedy approval of lung cancer ADCThe FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving competitors.
- Adicet's off-the-shelf CAR-T shows 50% kidney response in early lupus trialAn early-stage study of Adicet Bio's off-the-shelf gamma-delta CAR-T cell therapy reported encouraging results in patients with lupus nephritis. After a year of follow-up, half of the evaluable pa…